A clinical laboratory can receive a large repayment demand without the demand explaining whether the disputed testing was improperly coded, outside a coverage policy, insufficiently documented, not properly ordered, or included in an allegedly defective statistical sample. Those theories are not interchangeable. A laboratory defense should separate the clinical validity of a test, medical necessity for an individual beneficiary, the ordering requirements, billing and coding rules, and the contractor’s calculation. The fact that a technology can identify pathogens or genetic markers accurately does not, standing alone, establish that Medicare must pay for its use in every patient.
Sort the demand before reviewing the medical records
Obtain the notice, dates, program, contractor, claim list, amounts and stated denial rationales. Divide transactions by test panel, CPT or HCPCS code, ordering practitioner, referring practice, payor, service date, and applicable coverage document. Distinguish a claim-level denial from an extrapolated overpayment or a separate fraud investigation. The same lab may have multiple claims in review under different coverage standards or policy periods. An undifferentiated statement that all molecular tests are useful is unlikely to resolve a denial that turns on a specific billing or documentation condition.
Prepare a controlled claim matrix tying the contractor’s precise allegation to the submitted claim, remittance, laboratory information system, requisition and relevant medical record. Reconcile billing units, modifiers and duplicate or reversed claims. This helps identify calculation errors without implying that correcting arithmetic also resolves medical necessity.
Ordering rules: distinguish documented intent from a signature issue
42 C.F.R. § 410.32 sets important Medicare requirements for diagnostic tests, including appropriate ordering and documentation. CMS’s Lab Test Order Requirements guidance explains that diagnostic laboratory orders may be established through different forms of documentation, including a signed order or properly authenticated records supporting the treating professional’s intent. A missing handwritten signature on a requisition is not invariably the same as proof that no authorized order existed. The actual rules for the particular type of testing, documentation and clinical setting still control.
The lab must be able to identify the ordering clinician, what tests were intended, how the request was transmitted, and the clinical information relevant to the services billed. Where an order was communicated by telephone or another permitted channel, contemporaneous records on both sides of the transaction may matter. A later declaration may help explain existing records but must not falsely imply that a contemporaneous order or medical judgment existed when it did not.
Medical necessity is patient-specific, not a marketing claim
Medicare’s reasonable-and-necessary standard includes Social Security Act § 1862(a)(1)(A), codified at 42 U.S.C. § 1395y(a)(1)(A). A lab should examine the symptoms, diagnosis, clinical question and treatment decisions relevant to the testing. The medical record should explain why the treating clinician needed the result and how it related to management of that particular beneficiary. Where a proprietary molecular panel includes organisms or targets beyond the conventional test, distinguish clinical use from general technological capability. Avoid suggesting that more targets, greater analytical sensitivity or quicker turnaround automatically prove Medicare coverage.
A clinical literature review may support the reliability, potential utility or evidence base for a diagnostic method. It does not displace a date-specific National Coverage Determination, applicable Local Coverage Determination, coding article or other payment restriction. Identify the studies’ populations, clinical endpoints, limitations and relationship to the patient population under review. A peer-reviewed study from one context should not be stretched into a universal reimbursement requirement.
Coverage policy and coding can defeat an otherwise supported clinical claim
CMS maintains the Medicare Coverage Database for national and local coverage materials. Search using the relevant service, code and service date. A local coverage article may provide billing and diagnosis-code instructions that should be read alongside the LCD itself. Confirm whether a policy was effective, revised or retired on the date at issue. A laboratory that relies on the current online text without investigating historical versions risks applying a requirement that did not govern the original claim.
Coding issues may concern test identity, methodology, units, panel composition, modifiers or payer edits. Separate a wrong code from a test that should not have been ordered and a test that lacks required clinical documentation. Those findings need different corrective actions. CLIA certification and quality obligations may be relevant to the lab’s lawful operations, but compliance with laboratory quality standards does not by itself resolve whether a specific Medicare claim is covered.
Sampling and extrapolation deserve their own review
An extrapolated demand should be evaluated at two levels. At the claim level, identify the sampled tests that a reviewer improperly denied and the evidence that supports each one. At the statistical level, examine the universe, sample selection, strata, methodology, adjustment records and calculation, with expert assistance where appropriate. An overpayment computed from a deficient sample can misstate liability; a technically valid sample still depends on the individual claim determinations. Preserve all contractor datasets, workpapers and communications and track appeal dates separately from any production deadlines.
Make the laboratory’s operational story verifiable
A persuasive response can explain how clinicians order testing, how requisitions are verified, how results reach treating professionals, what quality controls exist, and how codes enter the claims system. That account must match the actual workflow and contemporaneous records. If a laboratory uses an RCM company, reference lab, marketing organization or management services company, obtain the relevant agreements and data responsibilities. Avoid assuming the outside vendor bears all legal risk for unsupported orders or claims.
Initial evidence and authorities
- Audit notice, claims and remittance data, sample and denial worksheets
- Patient-specific ordering evidence, diagnostic indications, test results and records supporting clinical use
- Applicable service-date NCD, LCD, billing articles and test codes
- LIS exports, requisition and reporting workflows, relevant vendor agreements and any CLIA findings
- CMS Laboratory Test Order Requirements
- CMS Medicare Coverage Database and Original Medicare appeals guidance
For different issues, see sampling and extrapolation challenges, Medicare appeal evidence requirements, and clinical laboratory counsel.
Editorial update: Brian M. O’Loughlin, JD, RN | Substantive revision October 24, 2026. This is original legal analysis of public sources, not an endorsement of a particular diagnostic platform.
Facing a laboratory audit? BOLO can help separate the legal bases for each denial, investigate the claim-level evidence and identify the appropriate response route. Request a matter review or call 609-200-6677. Do not transmit patient or laboratory records through public intake.
Attorney advertising. General educational material; no legal advice, outcome prediction or reimbursement guarantee. Service-date policy, payer and actual facts govern. Contact does not create an attorney-client relationship. See editorial standards.